AZD9056 Relative Bioavailability Study

NCT00908934 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: AZD9056 formulation Phase III 50 mg (T)
DRUG: AZD9056 formulation Phase IIb 50 mg (R)
DRUG: AZD9056 formulation Phase III 200 mg (T)
DRUG: AZD9056 formulation Phase IIb 200mg (R)

Sponsor

AstraZeneca